Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1989, the company has established itself as a leader in the development of innovative drug discovery and development services, particularly in the fields of central nervous system disorders and other therapeutic areas. With a strong focus on research and development, Suven Pharmaceuticals offers a diverse portfolio of products, including proprietary drug candidates and contract research services. The company is recognised for its unique approach to drug development, leveraging advanced technologies to enhance therapeutic efficacy. Suven's commitment to quality and innovation has positioned it favourably in the global market, earning accolades for its contributions to healthcare and significant milestones in clinical research. As it continues to expand its operational footprint, Suven Pharmaceuticals remains dedicated to improving patient outcomes through cutting-edge pharmaceutical solutions.
DitchCarbon Score
How does Suven Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Suven Pharmaceuticals Limited's score of 19 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Suven Pharmaceuticals Limited's reported carbon emissions
In 2023, Suven Pharmaceuticals Limited reported total carbon emissions of approximately 48,594,000 kg CO2e for Scope 1 and 33,723,000 kg CO2e for Scope 2. This represents a slight increase in Scope 1 emissions compared to 2022, where emissions were about 47,497,790 kg CO2e for Scope 1 and 35,462,000 kg CO2e for Scope 2. However, the company has made significant strides in reducing its emissions, achieving a reduction in Scope 2 emissions from 2022 to 2023. Looking ahead, Suven Pharmaceuticals has committed to a long-term net-zero target by 2050, encompassing all scopes of emissions. This commitment aligns with the Science Based Targets initiative (SBTi), indicating a proactive approach to climate action within the pharmaceutical sector. The company is currently in the process of establishing specific reduction targets to further enhance its sustainability efforts. Overall, Suven Pharmaceuticals Limited is actively working towards reducing its carbon footprint while adhering to industry standards and climate commitments, reflecting a growing awareness of environmental responsibility in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 47,497,790 | 00,000,000 | 00,000,000 |
| Scope 2 | 35,462,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Suven Pharmaceuticals Limited is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
